BioTuesdays

Tag - ALRN

Aileron Therapeutics Logo
Markets

HCW cuts Aileron Therapeutics PT to $1 from $2

H.C. Wainwright reduced its price target for Aileron Therapeutics (NASDAQ:ALRN) to $1 from $2, but maintained its “buy” rating, after the company reported “underwhelming” interim data from a Phase 1 study in non-small...

June 30, 2022
Aileron Therapeutics Logo
Markets

WB cuts Aileron Therapeutics to market perform

William Blair downgraded Aileron Therapeutics (NASDAQ:ALRN) to “market perform” after the company released interim data from a Phase trial of ALRN-6924 as a chemoprotectant in patients with non-small cell lung cancer...

June 29, 2022
Aileron Therapeutics Logo
Markets

HCW halves Aileron Therapeutics PT to $3

H.C. Wainwright lowered its price target for Aileron Therapeutics (NASDAQ:ALRN) to $3 from $6, citing the removal of lead drug candidate, ALRN-6924, in combination with Ibrance in murine double minute 2 (MDM2) gene...

March 31, 2020